AIIA Goa conducts induction programme for first batch of BAMS student

Ayurveda is one of the most advanced sciences of its times

Teijin and Axcelead to establish drug discovery research JV

The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.

Asahi Kasei completes construction of microcrystalline cellulose plant

With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC

Johnson & Johnson appoints Dr. John Reed as EVP, Pharmaceuticals, R&D

Univar Solutions expands ingredients portfolio through new distribution agreement with SI Group

Strategic partnership aims to support significant growth of the Ibuprofen product market in Brazil and is backed by Univar Solutions' state-of-the-art Solution Center in São Paulo, Brazil

NATCO files generic Olaparib Tablets in USA

Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer

Artificial intelligence facilitates low-cost drug repurposing, says GlobalData

The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.

Pfizer appoints Meenakshi Nevatia as MD and Additional Director

She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.

Dr. Reddy’s included in Bloomberg Gender-Equality Index for 6th year in a row

The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category

Janssen and Eli Lilly collaboration to address lack of pediatric therapies could rescue mirikizumab program, says GlobalData

The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).